Introduction
Oral squamous cell carcinoma is one of the most known cancers in the universe, with a degree of 300,000 new cases identified in 2012 (Ferlay et al., 2012) . The analysis underlying the cause of oral squamous cell carcinoma is not completely understood but it is believed that alcohol, tobacco usage, chewing the betel are the major influences which are involved in the formation of carcinogenesis (Chen et al., 2008) . The collection of genetic alteration leads to uncontrolled proliferation in the mutated oral squamous cell lines whereas the damage in the genetic components leads to an uncontrolled multiplication of mutant oral keratinocyte cells (Chianeh and Prabhu, 2014) . The cellular vital response functions of both chemotherapy and irradiation are the cause of apoptosis (Eriksson and Stigbrand, 2010; Jonathan et al., 1999; La Vecchia et al., 2004; Ocker and Hopfner, 2012; Ricci and Zong, 2006) .
The treatment possesses multi-modal activities comprises of radiotherapy, surgery, and chemotherapy (Seiwert and Cohen, 2005) but all these methods are still not satisfactory due to their adverse effects.
Cabozantinib is considered as a multi-targeted tyrosine kinase receptor with chiefly possessing MET, and vascular endothelial growth factor (VEGFR2) inhibition characteristics. MET is a hepatocyte growth factor which is widely expressed in adult tissues and incriminated in post-natal physiological and pathophysiological events. Cabozantinib is a TKI which targets three related pathways in MET, MTC, VEGFR2, and RET (Yakes et al., 2011) . Herein, we showed the anti-tumor effects of cabozantinib on two Oral squamous cell carcinoma cell lines , and probe into the potential underlying mechanisms.
Materials and Methods

Materials
Recombinant Human Hepatocyte Growth Factor (HGF), Dubecco's modified Eagle's medium (DMEM), fetal bovine serum and MTT were purchased from Life Techologies (Carlsbad, USA). Cabozantinib (Tradename: COMETRIQ) was purchased from Exelixis (San Francisco, USA). Crystal violet was purchased from Solarbio (Beijing, China). Propidium iodide, RNase, annexin VFICT/propidium iodide apoptosis detection kit and antibodies to MET, phosphorylated MET, cyclin B1, phosphorylated histone H3, cyclin A, cleaved caspase-3, cleaved PARP-1, FAK and phosphorylated FAK, β-actin, FAK specific siRNA were purchased from Cell Signaling Technology (Danvers, USA). PVDF membrane and chemiluminescent reagents were from EMD Millipore (Massachusets, USA). Antibody to pan-caspase inhibitor z-VAD-FMK was purchased from Santa-Cruz Biotechnology (Santa-Cruz, USA)
Cell lines and cell culture
The human oral squamous cell carcinoma cell lines BHY and HSC-3 were purchased from American Type Culture Collection (ATCC, USA). BHY and HSC-3 cells were routinely cultured with DMEM supplemented with 10% heat-inactivated fetal bovine serum. Cell cultures were maintained at 37°C incubator with an atmosphere of 5% CO2. To treat the cells with cabozantinib, cells were grown up to 60% confluence. The cells were then treated with various concentration of cabozantinib ranging from 0 to 1.0 µM for 0-48 hours. Cells treated with DMSO were used as the control for comparison. After the cells were treated with cabozantinib, trypsin was used to detach the cells and collected for posterior analysis.
MTT assay
The inhibition of cell growth by cabozantinib was studied in BHY and HSC-3 cells. Various concentrations of the cabozantinib for 24, 48 and 72 hours and the viability of the cells was assayed by MTT. Cell viability assay was carried out in a 24-well plate. BHY and HSC-3 cells at a density of 5,000 cells/well were grown in a 24-well plate (Corning, USA). After treatment with drug, the culture medium was replaced with fresh medium containing 10% MTT (5 mg/mL in PBS) and incubated at 37ºC for 4 hours. Then, the medium with MTT was discarded and DMSO was added to dissolve the newly formed formazan crystals. Absorbance was measured in a microplate reader (Sunrise, Tecan) at a 540 nm wavelength. The cell viability was calculated by normalizing the absorbance to control and the results were represented as a percentage of the control.
Colony formation assay
The colony formation of BHY and HSC-3 cells after treatment with cabozantinib was studied. Various concentrations of the cabozantinib for 24, 48 and 72 hours and the viability of the cells was assayed by MTT. 6-well plates (1,000 cells/well) at single cell density were used for colony forming assay. BHY and HSC-3 cells were pre-cultured for 24 hours. The cells were treated after 24 hours with the various concentration of cabozantinib or DMSO from 0 to 1.0 µM for additional 48 hours. The medium was replaced with fresh medium to allow the cell growth for 10 days. Methyl alcohol was used to fix the cells for 15 min and stained with crystal violet for 30 min. Colonies consisting of more than 50 cells were considered for counting. The colony forming ability of the cells treated with cabozantinib was normalized with the control cells without drug treatment.
Flow cytometry analysis
To know further about the inhibitory effect of cabozantinib on cell growth, flow cytometry was used to measure the cell cycle progression by DNA quantification. BHY and HSC-3 cells were pre-cultured for 24 hours in DMEM medium. Cells were treated with cabozantinib or DMSO and incubated for 24 hours. The cells were harvested by using trypsin and washed with PBS twice. The cells were fixed with ice-cold 75% ethanol at 20°C overnight and stained with 500 mL of propidum iodide at a concentration of 50 mg/mL containing 0.1% RNase (1 mg/mL) for 15 min in dark at room temperature for cell cycle assay. Annexin-V/propidum iodide double staining was used to study the role of cabozantinib in inducing apoptosis in oral squamous carcinoma cancer cells by quantifying the cells that undergo apoptosis. For apoptosis assay, the cabozantinibtreated cells were suspended in 100 mL of annexin-V-FITC binding buffer and 5 mL of annexin V-FITC and 5 mL of propidum iodide were used for staining in dark at room temperature. The stained cells were analyzed by flow cytometry (BD FACSCanto II, BD Biosciences, USA). The results were shown as mean values from three independent value.
Western blot analysis
To elucidate the role of cabozantinib in the cell cycle, the expression of G2/M phase regulatory proteins (Vermeulen et al., 2003) cyclin B1, cyclin A and phosphor-histone H3 by Western blot. The cells after the drug treatment were harvested and lysed using RIPA buffer with protease inhibitor cocktail (SigmaAldrich, USA). The protein concentration was quantified using BCA protein assay kit (Thermo Scientific, USA). The cell extracts were denatured and analyzed by SDS-PAGE. 12% SDS-PAGE was used to separate the proteins and transferred to PVDF membrane. The proteins in the membrane were blocked with 5% non-fat milk, and incubated with the corresponding primary. The membrane with proteins was then washed thrice with TBS and 0.05% Tween-20. After washing, it was incubated with HRP-conjugated secondary antibody raised in goat at 1:5000 dilution. Membranes were incubated with chemiluminscent substrate for 5 min and scanned with Image Quant LAS4000 (GE Life Sciences, USA). The density of the bands was estimated by standard methods and normalized by division with the density of control protein bands. All the experiments were done in triplicate.
SiRNA mediated FAK knockdown
Focal Adhesion Kinase, FAK is a non-receptor tyrosine kinase protein usually overexpressed and highly activated in most of the solid-tumors like oral squamous cell carcinoma (Kornberg, 1998; de Vicente et al., 2013) . FAK as a protein with multiple functions helps in regulating the signals from extracellular environment such as integrins and growth factor receptors. It is also involved in cell mitosis and organizing the cytoskeleton and acts as a protein scaffold (Schaller, 2010) . So, the anti-tumor function of cabozantinib through inhibition of cabozantinib was tested. SiRNA for FAK or control 
Statistical analyses
All experiments were done in triplicate. Graphpad prism software was used to analyze the data. Student's t-test or one-way ANOVA was used to differentiate between mean values. P-values of <0.05 were considered to be significant. Figure 1A shows that BHY and HSC-3 cells treated with cabozantinib had decreased cell viability with response to increase in concentration and time. Figure 1B shows that cells treated with cabozantinib at increasing concentration of 0.3, 0.6 and 1.2 μM could inhibit cell colony formation dependent on its concentration at 48 hours Cabozantinib has been reported to selectively inhibit MET, so whether the cytotoxic effect of cabozantinib is dependent on HGF/MET pathway inhibition was examined. BHY and HSC-3 cells with the various concentration of cabozantinib treated for 24 hours and MET and phosphorylated expression levels were identified by western blot. Figure 1C shows that MET and phosphorylated MET expression were not affected by the drug treatment in both BHY and HSC-3 cells. Meanwhile, BHY and HSC-3 cells pre-treated with HGF (15 ng/mL) for 6 hours and treated with 0.5 mM cabozantinib for another 24 hours. Figure 1D shows that HGF pretreatment did not affect the antiproliferative effect of cabozantinib in both the cell lines. Figure 2A shows that when compared to control cells, cabozantinib-treated cells in G2/M phase showed concentration-dependent increase in BHY and HSC-3 cells while a decrease in S phase accordingly with the concentration of cabozantinib. Figure 2B shows cyclin Apoptotic signaling pathway Figure 3A shows that total amount of cells with annexin -V increased with corresponding increase in cabozantinib concentration in both BHY and HSC-3 cells. Immunoblotting analysis revealed the expression levels of proteins associated with apoptosis such as cleaved-caspase-3 and cleaved-PARP were increased after treating with cabozantinib in a concentrationdependent manner as shown in Figure 3C . BHY and HSC-3 cells pre-treated with pan-caspases inhibitor z-VAD (30 mM) for 4 hours and then treated with 2mM of cabozantinib for 24 hours. Figure 3B shows that in both cell lines cabozantinib induced apoptosis were reduced by pan-caspase inhibitor, z-VAD. Meanwhile, z -VAD also blocked the cleavage of caspase-3 and PARPmediated by cabozantinib ( Figure 3D ). Figure 4A shows that decrease in total expression of phosphorylation at Tyr397 of FAK in both the cell lines with an increase in cabozantinib concentration. Through specific siRNA, FAK was knocked down in both BHY and HSC-3 cells resulted in decreased expression of total FAK and phosphorylated levels Tyr397 as shown in Figure 4B . Figure 4C shows the cell proliferation was reduced in FAK knockdown cells in both the cell lines. Moreover, knockdown of FAK can make the cancer cells more vulnerable to cabozantinib treatment as seen in Figure 4D .
Results
Cell growth and proliferation in BHY and HSC-3 cells
Effect of cabozantinib in cell cycle arrest
Down-regulation of FAK
Discussion
We studied the anticancer activity of cabozantinib and the mechanism in which cabozantinib acts on OSCC cell lines BHY and HSC-3 cells. It was found that there was strong cytotoxic activity by cabozantinib on proliferation and colony formation in both oral squamous cell carcinoma cell lines. Meanwhile, the total expression and MET phosphorylation were not affected by cabozantinib at the concentrations used for cytotoxicity. HGF, the ligand of MET, when treated with the cells, did not attenuate the inhibitory effect cabozantinib. This proves that cabozantinib can be used as an effective chemotherapeutic compound against oral squamous cell lines through MET independent signaling pathway. Some of the other MET inhibitors such as PHA-665752 and crizotinib caused cell cycle arrest in G0/G1 phase (data not shown), whereas cabozantinib treatment had caused a decrease in G2/M in both BHY and HSC-3 cells. The decrease in cyclin A and increase in cyclin B1 prove that cabozantinibtreated cells exit in G2 phase and enter into the mitotic phase. The cell cycle analysis reveals that both BHY and HSC-3 cells exit in G2 phase and undergoes mitotic inhibition after cabozantinib treatment This was further evaluated by the up-regulation histone H3 phosphorylation which usually gets phosphorylated at serine during cell mitosis by Aurora B (Hirota et al., 2005) .
The mode of action of chemotherapeutic drugs in anticancer treatment is targeting the cell apoptosis. Caspase enzymes plays an important role in apoptosis regulation extrinsically (Ola et al., 2011) . Caspase cascade was cleaved one by one after it gets the apoptotic signal from death receptor which then leads to activation of effector caspases especially caspase-3. Then the cellular substrates were cleaved by activated effector caspases such as poly-ADP-ribose polymerase and apoptotic signals were amplified to induce cell apoptosis (Porter and Janicke, 1999) . This study showed that cabozantinib induced cleavage of caspase-3 in a concentration dependent manner. When pan-caspases inhibitor z-VAD was used these effects were attenuated which indicates the important role of death receptor-mediated caspases activation in cabozantinib-induced apoptosis. The results suggest that caspases dependent apoptosis can be induced by cabozantinib in oral squamous carcinoma cells.
Many studies are providing satisfactory evidence that FAK overexpression and activation resulted in increases cell survival rate and proliferation, angiogenesis and metastasis and tumor invasion (Miyazaki et al., 2003; McLean et al., 2005) . A small molecule found as FAK scaffolding inhibitor Y15 can decrease cancer growth in thyroid cancer and leads to synergistic action with other chemotherapeutic agents (O'Brien et al., 2014) .
Some of the other FAK inhibitors such as VS-4718, PF-00562271 and VS-6063 have been tested clinically and have shown promising results in cancer patients.
So, it is clear that FAK signaling suppression can be targeted as an efficient way of cancer treatment (Lee et al., 2015) . The current study showed that the overall expression and phosphorylation of FAK was affected by cabozantinib treatment with response to concentration. siRNA-mediated silencing of FAK enhanced the anti-tumor activity of cabozantinib and reduced the cell proliferation showing that cabozantinib treatment is associated with FAK signaling pathway and not MET signaling pathway in OSCC cells. So the results proved that FAK signaling pathway can be blocked by cabozantinib treatment which can be a part of antitumor function of cabozantinib. To the best of our knowledge, this has to be the first report on FAK signaling inhibition by cabozantinib. This can give new insights to understand the molecular mechanism of cabozantinib. It is still unclear whether cabozantinib interacts directly or indirectly with FAK and blocks its activation and has to be explored further. 
Conclusion
Cabozantinib treatment can be used to suppress cell growth, affects cellular mitosis and also induces apoptosis in human oral squamous carcinoma cells with suppression of FAK signaling pathway.
